NZ743488A - Controlled-release cnp agonists with low initial npr-b activity - Google Patents
Controlled-release cnp agonists with low initial npr-b activityInfo
- Publication number
- NZ743488A NZ743488A NZ743488A NZ74348817A NZ743488A NZ 743488 A NZ743488 A NZ 743488A NZ 743488 A NZ743488 A NZ 743488A NZ 74348817 A NZ74348817 A NZ 74348817A NZ 743488 A NZ743488 A NZ 743488A
- Authority
- NZ
- New Zealand
- Prior art keywords
- controlled
- cnp agonist
- release
- npr
- activity
- Prior art date
Links
- 239000000556 agonist Substances 0.000 title abstract 9
- 238000013270 controlled release Methods 0.000 title abstract 5
- 230000002441 reversible effect Effects 0.000 abstract 2
- 125000004122 cyclic group Chemical group 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 230000004962 physiological condition Effects 0.000 abstract 1
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Endocrinology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Physical Education & Sports Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
Abstract
The present invention relates to a controlled-release CNP agonist from which CNP agonist is released with a release half-life of at least 6 hours under physiological conditions and which controlled-release CNP agonist has an EC50 that is at least 20-fold higher than the EC50 of the corresponding free CNP agonist and which released CNP agonist has an EC50 that is at most 3-fold higher than the EC50 of the corresponding free CNP agonist; to pharmaceutical compositions comprising said controlled-release CNP agonist; their use; and to methods of treatment. The controlled-release CNP agonist comprises a cyclic CNP peptide attached to a reversible linker at the ring position, where the reversible linker is further attached to a carrier comprising a branched PEG group.
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP16150631 | 2016-01-08 | ||
EP16179291 | 2016-07-13 | ||
EP16191462 | 2016-09-29 | ||
PCT/EP2017/050217 WO2017118703A1 (en) | 2016-01-08 | 2017-01-05 | Controlled-release cnp agonists with low initial npr-b activity |
Publications (1)
Publication Number | Publication Date |
---|---|
NZ743488A true NZ743488A (en) | 2023-02-24 |
Family
ID=57860818
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NZ743488A NZ743488A (en) | 2016-01-08 | 2017-01-05 | Controlled-release cnp agonists with low initial npr-b activity |
Country Status (7)
Country | Link |
---|---|
US (2) | US11389510B2 (en) |
EP (1) | EP3400022A1 (en) |
AU (2) | AU2017205693B2 (en) |
CA (1) | CA3007982C (en) |
IL (1) | IL259827A (en) |
NZ (1) | NZ743488A (en) |
WO (1) | WO2017118703A1 (en) |
Families Citing this family (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2017118707A1 (en) | 2016-01-08 | 2017-07-13 | Ascendis Pharma Growth Disorders A/S | Controlled-release cnp agonists with reduced side-effects |
HRP20221339T1 (en) | 2016-01-08 | 2023-01-06 | Ascendis Pharma Growth Disorders A/S | Cnp prodrugs with carrier attachment at the ring moiety |
IL293979B1 (en) | 2016-01-08 | 2024-04-01 | Ascendis Pharma Growth Disorders As | Controlled-release cnp agonists with increased nep stability |
EP3400021A1 (en) | 2016-01-08 | 2018-11-14 | Ascendis Pharma Growth Disorders A/S | Controlled-release cnp agonists with low npr-c binding |
MX2018008061A (en) | 2016-01-08 | 2018-08-23 | Ascendis Pharma Growth Disorders As | Cnp prodrugs with large carrier moieties. |
AU2017205693B2 (en) | 2016-01-08 | 2022-03-31 | Ascendis Pharma Growth Disorders A/S | Controlled-release CNP agonists with low initial NPR-B activity |
CA3037448A1 (en) | 2016-09-29 | 2018-04-05 | Ascendis Pharma Growth Disorders A/S | Combination therapy with controlled-release cnp agonists |
US20220118053A1 (en) | 2019-02-11 | 2022-04-21 | Ascendis Pharma Growth Disorders A/S | Dry Pharmaceutical Formulations of CNP Conjugates |
WO2023173086A1 (en) * | 2022-03-11 | 2023-09-14 | Avirmax Biopharma Inc. | Compositions and methods for expressing therapeutics |
WO2023227505A1 (en) | 2022-05-23 | 2023-11-30 | Ascendis Pharma Growth Disorders A/S | Liquid pharmaceutical formulations of cnp compounds |
Family Cites Families (59)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6624142B2 (en) | 1997-12-30 | 2003-09-23 | Enzon, Inc. | Trimethyl lock based tetrapartate prodrugs |
CA2345414A1 (en) | 1998-09-28 | 2000-04-06 | Santen Pharmaceutical Co., Ltd. | Eyedrops for promoting lacrimal secretion or treating keratoconjunctival disorders containing natriuretic peptide as active ingredient |
BRPI0203172B8 (en) | 2001-09-28 | 2021-05-25 | Nakao Kazuwa | pharmaceutical composition for achondroplasia |
ES2516041T3 (en) | 2001-10-10 | 2014-10-30 | Ratiopharm Gmbh | Remodeling and glycoconjugation of human growth hormone (hGH) |
US7122189B2 (en) | 2002-08-13 | 2006-10-17 | Enzon, Inc. | Releasable polymeric conjugates based on aliphatic biodegradable linkers |
BR0316560A (en) * | 2002-11-26 | 2005-10-04 | Nobex Corp | Natriuretic Compound Conjugate, Pharmaceutical Formulation, Method of Treating a Condition, Method of Preparing the Natriuretic Compound Conjugate, Modified Pro-Polynatriuretic Peptide Conjugate, Natriuretic Peptide Analog, hbnp Analogue, Compound, and Method of Preparing a Compound |
US7332164B2 (en) | 2003-03-21 | 2008-02-19 | Enzon Pharmaceuticals, Inc. | Heterobifunctional polymeric bioconjugates |
WO2004089280A2 (en) | 2003-04-08 | 2004-10-21 | Yeda Research And Development Co. Ltd. | Reversible pegylated drugs |
US8377917B2 (en) | 2004-03-23 | 2013-02-19 | Complex Biosystems Gmbh | Polymeric prodrug with a self-immolative linker |
GB2427360A (en) | 2005-06-22 | 2006-12-27 | Complex Biosystems Gmbh | Aliphatic prodrug linker |
CU23556A1 (en) | 2005-11-30 | 2010-07-20 | Ct Ingenieria Genetica Biotech | POLYMER STRUCTURE SIMILAR TO DENDRÍMERO FOR THE OBTAINING OF CONJUGATES OF PHARMACEUTICAL INTEREST |
US8450269B2 (en) | 2006-02-03 | 2013-05-28 | Prolor Biotech Ltd. | Long-acting growth hormone and methods of producing same |
WO2008031045A2 (en) | 2006-09-08 | 2008-03-13 | Mayo Foundation For Medical Education And Research | Aquaretic and natriuretic polypeptides lacking vasodilatory activity |
JP2010503707A (en) | 2006-09-15 | 2010-02-04 | エンゾン ファーマスーティカルズ インコーポレイテッド | Hindered ester biodegradable linkers for oligonucleotide delivery |
AR063621A1 (en) | 2006-11-09 | 2009-02-04 | Alcon Res Ltd | WATER INSOLUBLE POLYMERIC MATRIX FOR THE ADMINISTRATION OF PHARMACOS |
KR20080098216A (en) * | 2007-05-04 | 2008-11-07 | 한미약품 주식회사 | Natriuretic peptide conjugate using carrier substance |
EA021222B8 (en) | 2007-06-21 | 2015-11-30 | ИксЭль-ПРОТЕИН ГМБХ | Biologically active proteins having increased in vivo and/or in vitro stability |
CA2693616A1 (en) | 2007-07-11 | 2009-01-15 | Enzon Pharmaceuticals, Inc. | Polymeric drug delivery system containing a multi-substituted aromatic moiety |
US8377884B2 (en) | 2007-11-21 | 2013-02-19 | Biomarin Pharmaceutical Inc. | Variants of C-type natriuretic peptides |
MX2010008024A (en) * | 2008-02-01 | 2010-12-21 | Ascendis Pharma As | Prodrug comprising a self-cleavable linker. |
WO2009143412A2 (en) | 2008-05-23 | 2009-11-26 | Enzon Pharmaceuticals, Inc. | Polymeric systems containing intracellular releasable disulfide linker for the delivery of oligonucleotides |
WO2009156481A1 (en) | 2008-06-25 | 2009-12-30 | Ascendis Pharma As | Pegylated bnp |
WO2010033216A1 (en) | 2008-09-19 | 2010-03-25 | Nektar Therapeutics | Polymer conjugates of nesiritide peptides |
DK2393828T3 (en) | 2009-02-03 | 2017-01-23 | Amunix Operating Inc | Extended recombinant polypeptides and compositions comprising same |
PE20120792A1 (en) * | 2009-05-20 | 2012-07-27 | Biomarin Pharm Inc | TYPE C NATRIURETIC PEPTIDES VARIANTS |
EP2459227B1 (en) | 2009-07-31 | 2021-03-17 | Ascendis Pharma A/S | Prodrugs containing an aromatic amine connected by an amide bond to a carrier |
WO2011031441A1 (en) | 2009-08-28 | 2011-03-17 | The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Therapy with a chimeric molecule and a pro-apoptotic agent |
WO2011075471A2 (en) | 2009-12-18 | 2011-06-23 | Alcon Research, Ltd. | Novel npr-b agonists and methods of use for the treatment of c-type natriuretic peptide-mediated disorders |
WO2011082368A2 (en) | 2009-12-31 | 2011-07-07 | Enzon Pharmaceuticals, Inc | Polymeric conjugates of aromatic amine containing compounds including releasable urea linker |
US20130030359A1 (en) | 2010-01-22 | 2013-01-31 | Ascendis Pharma A/S | Dipeptide-based prodrug linkers for aromatic amine-containing drugs |
US9062094B2 (en) | 2010-01-22 | 2015-06-23 | Ascendis Pharma As | Dipeptide-based prodrug linkers for aliphatic amine-containing drugs |
US9561285B2 (en) | 2010-01-22 | 2017-02-07 | Ascendis Pharma As | Carrier-linked carbamate prodrug linkers |
WO2011123813A2 (en) | 2010-04-02 | 2011-10-06 | Amunix Operating Inc. | Binding fusion proteins, binding fusion protein-drug conjugates, xten-drug conjugates and methods of making and using same |
US8946405B2 (en) | 2010-05-05 | 2015-02-03 | Prolynx Llc | Controlled release from solid supports |
EP2566335B1 (en) | 2010-05-05 | 2016-06-29 | Prolynx Llc | Controlled release of active compounds from macromolecular conjugates |
EP2571510B1 (en) | 2010-05-21 | 2018-08-08 | XL-protein GmbH | Biosynthetic proline/alanine random coil polypeptides and their uses |
WO2013024047A1 (en) | 2011-08-12 | 2013-02-21 | Ascendis Pharma A/S | High-loading water-soluble carrier-linked prodrugs |
CN103857413A (en) | 2011-08-12 | 2014-06-11 | 阿森迪斯药物股份有限公司 | Carrier-linked treprostinil prodrugs |
CA2843503C (en) | 2011-08-12 | 2020-12-22 | Ulrich Hersel | Polymeric hyperbranched carrier-linked prodrugs |
AU2012296951B2 (en) | 2011-08-12 | 2016-09-15 | Ascendis Pharma A/S | Protein carrier-linked prodrugs |
EP3643306A3 (en) | 2011-08-12 | 2020-08-26 | Ascendis Pharma A/S | Carrier-linked prodrugs having reversible carboxylic ester linkages |
WO2013036857A1 (en) | 2011-09-07 | 2013-03-14 | Prolynx Llc | Sulfone linkers |
US20150087688A1 (en) | 2012-04-25 | 2015-03-26 | Ascendis Pharma A/S | Prodrugs of hydroxyl-comprising drugs |
TWI578995B (en) * | 2012-04-25 | 2017-04-21 | 第一三共股份有限公司 | Use of natriuretic peptide receptor npr-b agonist |
US10052366B2 (en) * | 2012-05-21 | 2018-08-21 | Alexion Pharmaceuticsl, Inc. | Compositions comprising alkaline phosphatase and/or natriuretic peptide and methods of use thereof |
JP6536871B2 (en) | 2013-12-02 | 2019-07-03 | 国立大学法人京都大学 | Preventive and therapeutic agent for FGFR3 disease and method of screening the same |
JPWO2015129812A1 (en) | 2014-02-27 | 2017-03-30 | 第一三共株式会社 | Drugs for growth disorders induced by steroid administration |
AU2015299055C1 (en) | 2014-08-06 | 2021-05-06 | Ascendis Pharma A/S | Prodrugs comprising an aminoalkyl glycine linker |
US20170368189A1 (en) | 2015-01-09 | 2017-12-28 | Ascendis Pharma Growth Disorders A/S | Cnp prodrugs |
US11202819B2 (en) | 2015-12-08 | 2021-12-21 | Biomarin Pharmaceutical Inc. | Use of C-type natriuretic peptide variants to treat osteoarthritis |
AU2017205693B2 (en) | 2016-01-08 | 2022-03-31 | Ascendis Pharma Growth Disorders A/S | Controlled-release CNP agonists with low initial NPR-B activity |
HRP20221339T1 (en) | 2016-01-08 | 2023-01-06 | Ascendis Pharma Growth Disorders A/S | Cnp prodrugs with carrier attachment at the ring moiety |
IL293979B1 (en) | 2016-01-08 | 2024-04-01 | Ascendis Pharma Growth Disorders As | Controlled-release cnp agonists with increased nep stability |
EP3400021A1 (en) | 2016-01-08 | 2018-11-14 | Ascendis Pharma Growth Disorders A/S | Controlled-release cnp agonists with low npr-c binding |
MX2018008061A (en) | 2016-01-08 | 2018-08-23 | Ascendis Pharma Growth Disorders As | Cnp prodrugs with large carrier moieties. |
WO2017118707A1 (en) | 2016-01-08 | 2017-07-13 | Ascendis Pharma Growth Disorders A/S | Controlled-release cnp agonists with reduced side-effects |
CA3037448A1 (en) | 2016-09-29 | 2018-04-05 | Ascendis Pharma Growth Disorders A/S | Combination therapy with controlled-release cnp agonists |
WO2020037285A1 (en) | 2018-08-16 | 2020-02-20 | Beyondspring Pharmaceuticals, Inc. | Method and composition for stimulating immune response |
US20220118053A1 (en) | 2019-02-11 | 2022-04-21 | Ascendis Pharma Growth Disorders A/S | Dry Pharmaceutical Formulations of CNP Conjugates |
-
2017
- 2017-01-05 AU AU2017205693A patent/AU2017205693B2/en active Active
- 2017-01-05 CA CA3007982A patent/CA3007982C/en active Active
- 2017-01-05 WO PCT/EP2017/050217 patent/WO2017118703A1/en active Application Filing
- 2017-01-05 NZ NZ743488A patent/NZ743488A/en unknown
- 2017-01-05 EP EP17700905.7A patent/EP3400022A1/en active Pending
- 2017-01-05 US US16/066,058 patent/US11389510B2/en active Active
-
2018
- 2018-06-05 IL IL259827A patent/IL259827A/en unknown
-
2022
- 2022-04-05 AU AU2022202280A patent/AU2022202280B2/en active Active
- 2022-06-13 US US17/839,390 patent/US20230103820A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
US11389510B2 (en) | 2022-07-19 |
IL259827A (en) | 2018-07-31 |
US20190328840A1 (en) | 2019-10-31 |
US20230103820A1 (en) | 2023-04-06 |
AU2017205693A1 (en) | 2018-06-07 |
EP3400022A1 (en) | 2018-11-14 |
CA3007982A1 (en) | 2017-07-13 |
AU2022202280A1 (en) | 2022-04-21 |
AU2017205693B2 (en) | 2022-03-31 |
CA3007982C (en) | 2023-12-19 |
AU2022202280B2 (en) | 2023-11-02 |
WO2017118703A1 (en) | 2017-07-13 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NZ743488A (en) | Controlled-release cnp agonists with low initial npr-b activity | |
PH12019501360A1 (en) | Glp-1 receptor agonists and uses thereof | |
NZ743487A (en) | Controlled-release cnp agonists with increased nep stability | |
PE20180571A1 (en) | INTERLEUKIN 23 RECEPTOR PEPTIDE INHIBITORS AND THEIR USE TO TREAT INFLAMMATORY DISEASES | |
NZ740644A (en) | Glucagon receptor agonists | |
PH12018502465A1 (en) | Mic-1 compounds and use thereof | |
MY187047A (en) | Selective pyy compounds and uses thereof | |
GEP20207151B (en) | Agents, Uses and Methods for the Treatment of Synucleinopathy | |
MX2016006053A (en) | Selective pyy compounds and uses thereof. | |
AR101742A1 (en) | CALCITONINE AND AMILINE RECEIVER AGONIST | |
JOP20210326A1 (en) | Natriuretic peptide receptor 1 antibodies and methods of use | |
MX2019013801A (en) | Mic-1 compounds and uses thereof. | |
MX2019009126A (en) | COMPOSITIONS AND METHODS FOR LONG TERM RELEASE OF GANADOTROPIN-RELEASING HORMONE (GnRH) ANTAGONISTS. | |
JOP20200004A1 (en) | Long-acting formulations | |
DOP2020000082A (en) | ORAL ADMINISTRATION OF GLP-1 PEPTIDE ANALOGUES | |
CL2022001227A1 (en) | npy2 receptor agonists | |
ECSP23003649A (en) | SOLUBLE NPY2 RECEPTOR AGONISTS BACKGROUND OF THE INVENTION | |
MX2018010194A (en) | Sustained release buprenorphine microspheres (srbm) and methods of use thereof. | |
PH12021551243A1 (en) | Oxyntomodulin peptide analog formulations | |
GEP20237486B (en) | Formulations of copanlisib | |
MX2019014604A (en) | Nasal composition. | |
EA201690966A1 (en) | NEW CONNECTION FOR THE TREATMENT OF HEAVY HYPOGLYCEMIA | |
MY171183A (en) | Polypeptide glycosylated with sialylated sugar chain | |
MX2020013684A (en) | Formulations/compositions comprising ibrutinib. | |
MX2020000752A (en) | Pharmaceutical combinations comprising an anti bst-1 antibody and a cytidine analogue. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PSEA | Patent sealed | ||
RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 05 JAN 2025 BY PAVIS PAYMENTS GMBH Effective date: 20231221 |